scholarly journals Design of a randomized controlled trial on the efficacy of a reproductive health survivorship care plan in young breast cancer survivors

2019 ◽  
Vol 77 ◽  
pp. 27-36 ◽  
Author(s):  
Shaylyn S. Stark ◽  
Loki Natarajan ◽  
Diana Chingos ◽  
Jennifer Ehren ◽  
Jessica R. Gorman ◽  
...  
2015 ◽  
Vol 22 (4) ◽  
pp. 252 ◽  
Author(s):  
M.A. O'Brien ◽  
E. Grunfeld ◽  
J. Sussman ◽  
G. Porter ◽  
M. Hammond Mobilio

Background The U.S. Institute of Medicine recommends that cancer patients receive survivorship care plans, but evaluations to date have found little evidence of the effectiveness of such plans. We conducted a qualitative follow-on study to a randomized controlled trial (rct) to understand the experiences of family physicians using survivorship care plans to support the follow-up of breast cancer patients.MethodsA subset of family physicians whose patients were enrolled in the parent rct in Ontario and Nova Scotia were eligible for this study. In interviews, the physicians discussed survivorship care plans (intervention) or usual discharge letters (control), and their confidence in providing follow-up cancer care.Results Of 123 eligible family physicians, 18 (10 intervention, 8 control) were interviewed. In general, physicians receiving a survivorship care plan found only the 1-page care record to be useful. Physicians who received only a discharge letter had variable views about the letter’s usefulness; several indicated that it lacked information about potential cancer- or treatment-related problems. Most physicians were comfortable providing care 3–5 years after diagnosis, but desired timely and informative communication with oncologists. Conclusions Although family physicians did not find extensive survivorship care plans useful, discharge letters might not be sufficiently comprehensive for follow-up breast cancer care. Effective strategies for two-way communication between family physicians and oncologists are still lacking.


2017 ◽  
Vol 19 (4) ◽  
pp. 456-464 ◽  
Author(s):  
Richard R. Reich ◽  
Cecile A. Lengacher ◽  
Thomas W. Klein ◽  
Cathy Newton ◽  
Steve Shivers ◽  
...  

Purpose: The purpose of this substudy of a large randomized controlled trial was to evaluate the efficacy of the Mindfulness-Based Stress Reduction (Breast Cancer) (MBSR[BC]) program compared to usual care (UC) in normalizing blood levels of pro-inflammatory cytokines among breast cancer survivors (BCS). Method: A total of 322 BCS were randomized to either a 6-week MBSR(BC) program or a UC. At baseline and 6 and 12 weeks, 10 ml of venous blood and demographic and clinical data were collected and/or updated. Plasma cytokines (interleukin [IL]-1β, IL-6, IL-10, tumor necrosis factor [TNF] α, transforming growth factor [TGF] β1, soluble tumor necrosis factor receptor [sTNFR] 1) were assayed. Linear mixed models were used to assess cytokine levels across three time points (baseline and 6 and 12 weeks) by group (MBSR[BC] vs. UC). Results: Of the six measured cytokines, three were nondetectable at rates greater than 50% (IL-10, IL-1β, TGF-β1) and, because of overall low prevalence, were not analyzed further. For the remaining cytokines (TNFα, IL-6, sTNFR1), results showed that TNFα and IL-6 increased during the follow-up period (between 6 and 12 weeks) rather than during the MBSR(BC) training period (between baseline and 6 weeks), while sTNFR1 levels did not change significantly across the 12-week period. Conclusions: Study results suggest that MBSR(BC) affects cytokine levels in BCS, mainly with increases in TNFα and IL-6. The data further suggest that B-cell modulation may be a part of immune recovery during breast cancer management and that increases in TNFα and IL-6 may be markers for MBSR(BC)-related recovery.


Cancer ◽  
2014 ◽  
Vol 121 (8) ◽  
pp. 1231-1240 ◽  
Author(s):  
Julienne E. Bower ◽  
Alexandra D. Crosswell ◽  
Annette L. Stanton ◽  
Catherine M. Crespi ◽  
Diana Winston ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document